Jia-Bao Zhang , Guo-Dong Lu , Dan-Ni Sun , Peng Ding , Ya-Kun Chen , Yan-Yan Zhou , Yi-Ting Chen , Mudan Cai , Jong Hoon Ryu , Pei Wang , Yong-Ping Liang
{"title":"Pellitorine protects chronic restraint stress-induced cognitive deficits via inhibiting neural inflammation and ferroptosis","authors":"Jia-Bao Zhang , Guo-Dong Lu , Dan-Ni Sun , Peng Ding , Ya-Kun Chen , Yan-Yan Zhou , Yi-Ting Chen , Mudan Cai , Jong Hoon Ryu , Pei Wang , Yong-Ping Liang","doi":"10.1016/j.intimp.2025.115166","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>It has not been known that pellitorine, an active ingredient of <em>Piper sarmentosum Roxb.</em> with therapeutic effects against epilepsy and anxiety disorders, has the neurological effects. Our study aimed to investigate the therapeutic potential of pellitorine in addressing chronic restraint stress (CRS)-associated cognitive deficits.</div></div><div><h3>Methods</h3><div>The CRS mouse model was treated with pellitorine and subjected to depression-like behavior assessments. Neuronal survival was evaluated through histological and Nissl staining. Immunoblotting assays were conducted to examine the expression levels of signaling pathway proteins. Immunofluorescent staining, flow cytometry, and RNA sequencing were utilized to further elucidate the pathological and molecular changes in pellitorine-treated CRS mice.</div></div><div><h3>Results</h3><div>Behavioral experiments demonstrated that pellitorine treatment significantly alleviated depression-like behaviors and improved cognitive function in CRS mice. Histological analysis revealed a marked reduction in neuronal loss following pellitorine administration. Transcriptomic profiling indicated that pellitorine suppressed ferroptosis-associated signaling pathways and neuroinflammation. Notably, the expression of anti-ferroptosis factors, including GPX4, DHODH, and FSP1, was decreased in CRS mice but restored by pellitorine treatment. In addition, pellitorine prevented neuronal loss, preserved the expression of neuroprotective molecules such as BDNF, Nrf2, HO-1, phosphorylated-CREB, and phosphorylated-ERK1/2, and reduced the protein levels of inflammation-related markers including NLRP3, HMGB1, and NF-κB. Immunofluorescent staining and flow cytometry analyses further showed that pellitorine treatment reduced the number of activated microglia, as indicated by decreased Iba-1<sup>+</sup>, TREM2<sup>+</sup>, CD86<sup>+</sup>, and CX3CR1<sup>+</sup> cell populations in the hippocampus. Importantly, pellitorine did not exhibit any observable neurotoxic effects in healthy control mice.</div></div><div><h3>Conclusions</h3><div>Our findings demonstrate that pellitorine protects against CRS-induced cognitive deficits, neural inflammation, and ferroptosis, highlighting its promise as a therapeutic agent for mental health issues.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"162 ","pages":"Article 115166"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925011567","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
It has not been known that pellitorine, an active ingredient of Piper sarmentosum Roxb. with therapeutic effects against epilepsy and anxiety disorders, has the neurological effects. Our study aimed to investigate the therapeutic potential of pellitorine in addressing chronic restraint stress (CRS)-associated cognitive deficits.
Methods
The CRS mouse model was treated with pellitorine and subjected to depression-like behavior assessments. Neuronal survival was evaluated through histological and Nissl staining. Immunoblotting assays were conducted to examine the expression levels of signaling pathway proteins. Immunofluorescent staining, flow cytometry, and RNA sequencing were utilized to further elucidate the pathological and molecular changes in pellitorine-treated CRS mice.
Results
Behavioral experiments demonstrated that pellitorine treatment significantly alleviated depression-like behaviors and improved cognitive function in CRS mice. Histological analysis revealed a marked reduction in neuronal loss following pellitorine administration. Transcriptomic profiling indicated that pellitorine suppressed ferroptosis-associated signaling pathways and neuroinflammation. Notably, the expression of anti-ferroptosis factors, including GPX4, DHODH, and FSP1, was decreased in CRS mice but restored by pellitorine treatment. In addition, pellitorine prevented neuronal loss, preserved the expression of neuroprotective molecules such as BDNF, Nrf2, HO-1, phosphorylated-CREB, and phosphorylated-ERK1/2, and reduced the protein levels of inflammation-related markers including NLRP3, HMGB1, and NF-κB. Immunofluorescent staining and flow cytometry analyses further showed that pellitorine treatment reduced the number of activated microglia, as indicated by decreased Iba-1+, TREM2+, CD86+, and CX3CR1+ cell populations in the hippocampus. Importantly, pellitorine did not exhibit any observable neurotoxic effects in healthy control mice.
Conclusions
Our findings demonstrate that pellitorine protects against CRS-induced cognitive deficits, neural inflammation, and ferroptosis, highlighting its promise as a therapeutic agent for mental health issues.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.